By Yafo Life Sciences
December 27th, 2021 (Shanghai) — We are glad to announce that Richard Wang, the Founder, Chairman and CEO of Neukio Biotherapeutics(星奕昂生物), has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
Speech Topic: Status Quo and Future Development of Cell Therapy in China
About the speaker
Dr. Richard Wang, Founder, Chairman and CEO of Neukio has extensive expertise and R&D management experience in the biopharmaceutical field in the US and China, and served as founding CEO of Fosun Kite, a joint venture between Fosun Pharma and Kite Pharma prior to establishing Neukio. He led Fosun Kite completed CMC tech transfer of Yescarta, construction of GMP production facilities, registration clinical trials and NDA filing in less than three years, and made Yescarta the first marketing approved CAR-T product in China by the NMPA.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
If you are interested in listening to the live event, please register at https://biotochina.org/register/
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: